Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919971 | 0.82 | TSHR (0.42) | MEN1KMT2A | |
| SCHEMBL2152255 | 0.74 | KDM4E (0.46) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL378799 | 0.72 | OPRM1 (0.70) | OPRM1MEN1KMT2A | |
| SCHEMBL12983803 | 0.71 | PPIA (0.40) | MEN1KMT2AKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2636222 | 0.71 | OPRM1 (0.68) | OPRM1MEN1KMT2A | |
| SCHEMBL3334735 | 0.70 | TLR2 (0.53) | OPRM1 | |
| SCHEMBL21822086 | 0.68 | ALDH1A1 (0.51) | MEN1KMT2APOLBALDH1A1 | |
| SCHEMBL28780646 | 0.68 | KDM4E (0.41) | MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL25955678 | 0.68 | TOP2A (0.52) | MEN1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL7326235 | 0.68 | OPRM1 (0.56) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858629-B2 | Substituted imidazole 4-carboxamides as cholecystokinin-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2010178-B1 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090239862-A1 | 3-{(3S)-4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-3 -[(isopropylamino)carbonyl]-1-piperazinyl}-1-naphthoic acid, useful for the treatment, control, or prevention of obesity and diabetes | MERCK SHARP & DOHME CORP. | 2009-09-24 | — | — | US | disclosed |
| EP-2010178-A4 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-04-29 | — | — | EP | disclosed |
| EP-2010178-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120688-A2 | SUBSTITUTED IMIDAZOLE 4-CARBOXAMIDES AS CHOLECYSTOKININ-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239862-A1 | 3-{(3S)-4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-3 -[(isopropylamino)carbonyl]-1-piperazinyl}-1-naphthoic acid, useful for the treatment, control, or prevention of obesity and diabetes | CCKAR, CCKBR, GIPR | OPRM1 541/4885MEN1 3022/4885KMT2A 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.